Pharmaceutical companies are frequently involved in clinical trials in general practice, and this may trigger an increase in the use of the sponsoring company's products due to the physicians' experience with these products. This effect may be further strengthened by close physician-company cooperation, which may create physician loyalty toward the company. The effect of participation in company-sponsored studies on drug preferences has not been evaluated in primary care.
Morten Andersen, M.D., Ph.D., of the University of Southern Denmark, Odense, and colleagues investigated the effects of physicians participating in a pharmaceutical company-sponsored clinical trial that was aimed at improving patients' use of asthma medicine. The study compared 10 practices that were conducting the trial on asthma medicine with 165 control (nontrial-conducting) practices in Funen County, Denmark. The study included 5,439 patients treated with asthma drugs from the trial-conducting practices and 59,574 patients from the control practices.
The researchers found that the prevalence of inhaled steroid use among asthma patients increased from 68.5 percent at baseline to 72.9 percent during the second observation year in trial-conducting practices and from 69.1 percent to 73.3 percent in control (nontrial-conducting) practices. There was no impact of participating in the trial on physicians' adherence to international treatment guidelines. Both trial-conducting and control practices had a gradually increased use of the trial sponsor's inhaled corticosteroids, from 74.8 percent to 81.5 percent in trial-conducting practices and from 73.6 percent to 76.6 percent in control practices. Trial-conducting practices were 2
Contact: Morten Andersen, M.D., Ph.D.
JAMA and Archives Journals